

13 November 2006

Market Developments – Antisense Technology

- **ISIS Pharmaceuticals Inc reports positive Phase 2 data on its 2nd generation antisense drug ISIS 301012**
- **Data provides further validation for 2nd generation antisense drug development programs**

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results from two Phase 2 clinical trials of its 2nd generation antisense drug, ISIS 301012 presented at the American Heart Association Annual Scientific Sessions in Chicago. In the first study reported, patients with high cholesterol on stable doses of statins were treated with ISIS 301012 for five weeks. Patients who received 300 mg/week of ISIS 301012 in this study achieved a 51% reduction in LDL-cholesterol (LDL-C), a 42% reduction in total cholesterol (TC), and a 41% reduction in triglycerides (TG) beyond the levels achieved with statins alone. Isis also presented new results from an ongoing study in which patients with high cholesterol were treated for three months with 300 mg/week of ISIS 301012 as a single agent. Data from this study for dose cohorts through 200 mg/week were previously reported. In this study, increasing the dose of ISIS 301012 to 300 mg/week further reduced atherogenic lipids, with improvements in LDL-C, TC and TG of 62%, 46% and 43%, respectively.

In addition, in these studies ISIS 301012 continued to demonstrate a strong safety profile -- as a single agent and when co-administered with statins -- in every dose cohort presented. The drug was well-tolerated in both studies.

Isis Pharmaceuticals Inc is a strategic technology partner and major shareholder of Antisense Therapeutics Limited. Antisense Therapeutics' lead compound, ATL1102, a 2nd generation antisense inhibitor for Multiple Sclerosis (MS), was in-licensed from Isis. ATL1102 is currently undergoing Phase 2a clinical trials in patients with MS.

The results reported by Isis Pharmaceuticals on ISIS 301012 provide important further validation of the successful clinical application of 2nd generation antisense drugs.

For further details regarding the results from Isis' Phase 2 clinical trial of ISIS 301012 refer to the announcement posted at www.isispharm.com.

About Antisense Therapeutics Limited

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. ANP's major shareholders include Circadian Technologies Limited (ASX: CIR) and Isis Pharmaceuticals Inc (NASDAQ: ISIS).

About Isis Pharmaceuticals, Inc

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 14 drugs in development. Isis' drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases. Isis' partners are focused in disease areas such as ocular, viral and neurodegenerative diseases, and cancer. In its Ibis Biosciences(TM) division, Isis is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

Contact Information:

Website: www.antisense.com.au
Managing Director – Mark Diamond +61 3 9827 8999
Company Secretary – Phillip Hains +61 3 9824 5254
Media – Market Connect (Simon Watkin) +61 3 9686 9931